/TWST
TWST Stock - Twist Bioscience Corporation
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$32.51+1.85%
+$0.59 (+1.85%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.58
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).96
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.30
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+23.0%upside
Target: $39.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TWST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$32.18 – $32.84
TARGET (TP)$40.00
STOP LOSS$29.91
RISK/REWARD1:2.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.24
52W High$55.33
52W Low$23.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $376.57M | $312.97M | $245.11M | $203.56M | $132.33M |
| Gross Profit | $191.00M | $133.35M | $89.73M | $84.23M | $51.71M |
| Gross Margin | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% |
| Operating Income | $-136,259,000 | $-220,831,000 | $-217,159,000 | $-234,776,000 | $-152,726,000 |
| Net Income | $-77,670,000 | $-208,726,000 | $-204,618,000 | $-217,863,000 | $-152,098,000 |
| Net Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% |
| EPS | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 |
Company Overview
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$42
Average Target
↑ 29.6% Upside
Now
$27
Low
$42
Average
$60
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 4th 2025 | Stephens | Initiation | Overweight | $41 |
| December 13th 2024 | Wolfe Research | Initiation | Outperform | $60 |
| June 4th 2024 | Guggenheim | Initiation | Buy | $53 |
| January 17th 2024 | Goldman | Upgrade | Buy | $45← $25 |
| September 27th 2023 | Berenberg | Initiation | Buy | $27 |
| January 5th 2023 | Scotiabank | Initiation | Sector Outperform | $33 |
| January 3rd 2023 | Evercore ISI | Upgrade | Outperform | $36← $28 |
Earnings History & Surprises
TWSTBeat Rate
78%
Last 18 quarters
Avg Surprise
+8.4%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$-0.45
Q4 2025
EPS Surprise History
Q1 24
+6.3%
$-0.75vs$-0.80
Q2 24
+6.0%
$-0.79vs$-0.84
Q3 24
-8.9%
$-0.86vs$-0.79
Q4 24
+17.4%
$-0.59vs$-0.71
Q1 25
+14.5%
$-0.53vs$-0.62
Q2 25
-17.9%
$-0.66vs$-0.56
Q3 25
+13.0%
$-0.47vs$-0.54
Q4 25
+10.0%
$-0.45vs$-0.50
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 2, 2026 | $-0.49 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.50 | $-0.45 | +10.0% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $-0.54 | $-0.47 | +13.0% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $-0.56 | $-0.66 | -17.9% | ✗ MISS |
Q1 2025 | Feb 3, 2025 | $-0.62 | $-0.53 | +14.5% | ✓ BEAT |
Q4 2024 | Nov 18, 2024 | $-0.71 | $-0.59 | +17.4% | ✓ BEAT |
Q3 2024 | Aug 2, 2024 | $-0.79 | $-0.86 | -8.9% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-0.84 | $-0.79 | +6.0% | ✓ BEAT |
Q1 2024 | Feb 2, 2024 | $-0.80 | $-0.75 | +6.3% | ✓ BEAT |
Q4 2023 | Nov 17, 2023 | $-0.94 | $-0.81 | +13.8% | ✓ BEAT |
Q3 2023 | Aug 4, 2023 | $-1.14 | $-1.01 | +11.4% | ✓ BEAT |
Q2 2023 | May 5, 2023 | $-1.09 | $-1.06 | +2.8% | ✓ BEAT |
Q1 2023 | Feb 3, 2023 | $-1.09 | $-0.74 | +32.1% | ✓ BEAT |
Q4 2022 | Nov 18, 2022 | $-1.28 | $-0.91 | +28.9% | ✓ BEAT |
Q3 2022 | Aug 5, 2022 | $-1.30 | $-1.08 | +16.9% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-1.26 | $-1.24 | +1.6% | ✓ BEAT |
Q1 2022 | Feb 4, 2022 | $-1.08 | $-0.91 | +15.7% | ✓ BEAT |
Q4 2021 | Nov 22, 2021 | $-0.80 | $-0.84 | -5.0% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | $-0.76 | $-0.82 | -7.9% | ✗ MISS |
Latest News
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $39
📈 PositiveBenzinga•Dec 15, 2025, 09:11 PM•Also:
Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $37
➖ NeutralBenzinga•Nov 17, 2025, 02:55 PM•Also:
Twist Bioscience Sees Q1 Sales $100.000M-$101.000M vs $100.337M Est
➖ NeutralBenzinga•Nov 14, 2025, 12:24 PM
Twist Bioscience Sees FY2026 Sales $425.000M-$435.000M vs $374.691M Est
📈 PositiveBenzinga•Nov 14, 2025, 12:24 PM
Twist Bioscience Q4 EPS $(0.45) Misses $(0.43) Estimate, Sales $99.009M Beat $97.317M Estimate
➖ NeutralBenzinga•Nov 14, 2025, 12:24 PM
Stephens & Co. Initiates Coverage On Twist Bioscience with Overweight Rating, Announces Price Target of $41
📈 PositiveBenzinga•Nov 4, 2025, 01:04 PM
Evercore ISI Group Maintains Outperform on Twist Bioscience, Lowers Price Target to $42
➖ NeutralBenzinga•Oct 7, 2025, 06:02 PM
Twist Bioscience And Element Biosciences Launch Rapid Trinity Freestyle Workflow, Enabling End-to-End Sequencing In 5 Hours On AVITI Platforms
📈 PositiveBenzinga•Oct 6, 2025, 12:12 PM
Twist Bioscience And Synthetic Design Lab Collaborate For Research Activities
📈 PositiveBenzinga•Sep 2, 2025, 12:15 PM
Twist Bioscience Launches Oncology DNA Comprehensive Genomic Profiling Panel
📈 PositiveBenzinga•Aug 19, 2025, 12:07 PM
Frequently Asked Questions about TWST
What is TWST's current stock price?
Twist Bioscience Corporation (TWST) is currently trading at $32.51 per share. The stock has moved +1.85% today.
What is the analyst price target for TWST?
The average analyst price target for TWST is $40.00, based on 1 analyst.
What sector is Twist Bioscience Corporation in?
Twist Bioscience Corporation operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is TWST's market cap?
Twist Bioscience Corporation has a market capitalization of $1.94 billion, making it a small-cap company.
Does TWST pay dividends?
No, Twist Bioscience Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBGM
BGM Group Ltd.
$4.36
Mkt Cap: $0.9B
CLOV
Clover Health Investments, Corp.
$2.58
Mkt Cap: $1.3B
EWTX
Edgewise Therapeutics, Inc.
$25.55
Mkt Cap: $2.7B
GPCR
Structure Therapeutics Inc.
$64.94
Mkt Cap: $3.7B
GRDN
Guardian Pharmacy Services, Inc.
$31.54
Mkt Cap: $2.0B
MESO
Mesoblast Limited
$19.48
Mkt Cap: $2.5B
PRCT
PROCEPT BioRobotics Corporation
$32.06
Mkt Cap: $1.8B
QDEL
QuidelOrtho Corporation
$28.95
Mkt Cap: $2.0B
QURE
uniQure N.V.
$23.99
Mkt Cap: $1.3B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to TWST for comparison